Latest Breaking News On - மிட்‌ஸ்யூபீஶி தனபெ பார்மா - Page 10 : comparemela.com

Share this article Share this article JERSEY CITY, N.J., Jan. 7, 2021 /PRNewswire/  Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced revisions to the REFINE-ALS biomarker study protocol to address the safety of people with amyotrophic lateral sclerosis (ALS) during the pandemic. The amendment gives patients the ability to consent to participate virtually, with the option to utilize telemedicine and home health agencies in lieu of hospital or in-office visits. In an effort to address the evolving concerns of the ALS community this year, we made it a priority to do what we can to support them during these unprecedented times, said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs, MTPA. With that in mind, we are thankful to be able to offer a potential alternative for patients to be able to participate in the REFINE-ALS study in a virtual setting when in-person assessments are not possible, enabling us to continue fostering scientific knowledge.

United statesCh ungch ong namdoSouth koreaGustavoa suarez zambranoDebbie etchisonTanabe pharmaJames berryNeurological clinical research instituteMitsubishi tanabe pharma america incMitsubishi tanabe pharma corporationDrug administrationOverview of mitsubishi tanabe pharma corporationMitsubishi tanabe pharma holdings america incMitsubishi tanabe pharma americaVice presidentMedical affairs